Form 4: Precigen COO Sells Shares Under 10b5-1 Plan

Precigen, Inc. Chief Operating Officer Rutul R. Shah reported the sale of 42,924 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Rutul R. Shah, Chief Operating Officer of Precigen, Inc. (PGEN), reported a transaction on June 29, 2026.
• Shah sold 42,924 shares of common stock at a price of $5.85 per share.
• This sale was conducted under a Rule 10b5-1 trading plan, which is designed to satisfy affirmative defense conditions for insider trading.
• Following the sale, Shah beneficially owns 497,751 shares of common stock.
• Additionally, Shah acquired 42,924 shares of common stock at a price of $2.33 per share, also under a 10b5-1 plan.
• These acquired shares are linked to vested stock options with an exercise price of $2.33 and an expiration date of February 2, 2032.
• After these transactions, Shah beneficially owns 157,076 derivative securities (stock options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While an executive selling shares can be a negative signal, the execution under a 10b5-1 plan mitigates concerns about insider trading and suggests a pre-determined strategy.

Positives

• The sale of shares was executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-trading-related activity.
• The acquisition of shares at a lower price ($2.33) compared to the sale price ($5.85) could represent a favorable cost basis for future potential gains.
• The stock options are fully vested, providing flexibility for future exercise.

Negatives

• The COO sold a significant number of shares (42,924), which could be interpreted negatively by the market.
• The sale price of $5.85 per share is lower than the exercise price of some previously held options, though this is offset by the acquisition at $2.33.

Risks

• The sale of shares by a key executive could signal a lack of confidence in the company's immediate future prospects, although the 10b5-1 plan mitigates this interpretation.
• The company's stock price performance is subject to market volatility and the success of its product pipeline.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The future outlook for Precigen, Inc. would be detailed in other SEC filings such as 10-Q or 10-K reports.

Management Comments

• The sale of shares was conducted pursuant to the terms of a 10b5-1 plan adopted by the reporting person.
• The stock options are fully vested.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common in the biotechnology and pharmaceutical sectors. The use of 10b5-1 plans by executives is a standard practice to manage personal stock sales while adhering to insider trading regulations, especially in a volatile industry like biotech where stock prices can fluctuate significantly based on clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders: May view the sale of shares by a COO with some concern, but the 10b5-1 plan provides a degree of reassurance that it's not based on non-public information.
• Employees: May interpret the sale as a sign of the COO's personal financial planning rather than a reflection of company performance, especially given the 10b5-1 plan.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific insider transaction.

Next Steps

• Continued monitoring of Precigen, Inc.'s stock performance and future SEC filings.
• Observation of any further transactions by company insiders.

Key Dates

Recommendation

The filing reports routine insider transactions under a 10b5-1 plan. While the sale of shares by an executive can be a negative indicator, the pre-arranged nature of the trade under a compliance plan suggests it is not based on new, adverse material information. The acquisition of shares at a lower price also adds a layer of complexity. Without additional context on the company's performance or future prospects from other filings, a 'hold' recommendation is prudent, suggesting investors maintain their current positions pending further information.

Keywords

Precigen, PGEN, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Stock Options, Beneficial Ownership, Rutul R. Shah, Chief Operating Officer